Journal of Headache and Pain

Papers
(The median citation count of Journal of Headache and Pain is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition600
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II297
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis130
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine112
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study100
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials79
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache72
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation67
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency62
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients61
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study54
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China54
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia53
Debate: Are cluster headache and migraine distinct headache disorders?53
Measuring interictal burden among people affected by migraine: a descriptive survey study46
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke44
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine43
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks42
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine41
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey37
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine37
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results36
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury36
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States35
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI34
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study34
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study33
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting33
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs32
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain32
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas32
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study32
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study31
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model30
Development and validation of a novel model for characterizing migraine outcomes within real-world data30
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients30
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study29
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study29
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study29
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients28
Tracking the evolution of non-headache symptoms through the migraine attack27
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-201927
Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials27
Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients26
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis26
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)26
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients26
Contribution of tetrodotoxin-resistant persistent Na+ currents to the excitability of C-type dural afferent neurons in rats26
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study26
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study26
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental ch25
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review25
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure25
Genome-wide analysis identified novel susceptible genes of restless legs syndrome in migraineurs25
Effects of a history of headache and migraine treatment on baseline neurocognitive function in young athletes24
Insulin sensitizes neural and vascular TRPV1 receptors in the trigeminovascular system24
Potentiation of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine24
Correction: Applying a biopsychosocial model to migraine: rationale and clinical implications24
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study24
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients23
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab23
Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 rece23
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation23
CGRP-induced migraine-like headache in persistent post-traumatic headache attributed to mild traumatic brain injury23
The economic and personal burden of cluster headache: a controlled cross-sectional study22
Migraine-relevant sex-dependent activation of mouse meningeal afferents by TRPM3 agonists22
Long term evaluation of a multidisciplinary trigeminal neuralgia service22
Long COVID headache22
Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience21
Interictal osmophobia is associated with longer migraine disease duration21
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database21
Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis21
The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study20
Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan20
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results20
Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study20
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update20
The Global Campaign turns 18: a brief review of its activities and achievements19
Cortical spreading depression can be triggered by sensory stimulation in primed wild type mouse brain: a mechanistic insight to migraine aura generation19
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms19
Correction to: Hyperbaric oxygen attenuates neuropathic pain and reverses inflammatory signaling likely via the Kindlin-1/Wnt-10a signaling pathway in the chronic pain injury model in rats19
Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup19
TIME, to move forward? comment on “a universal outcome measure for headache treatments, care-delivery systems and economic analysis”19
0.11177897453308